Vitreous IGFBP-3 effects on müller cell proliferation and tractional force generation

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 1, 2012, Pages 93-99

  King, Jeffery L ^a   Guidry, Clyde ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN GEL; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT PROTEIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; COLLAGEN TYPE 1; IGFBP3 PROTEIN, HUMAN; KI 67 ANTIGEN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; EXTRACELLULAR MATRIX; HUMAN; MUELLER CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SWINE; VITREOUS BODY; ANIMAL; CELL ADHESION; CELL CULTURE; CELL MOTION; CYTOLOGY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GLIA; METABOLISM; PHASE CONTRAST MICROSCOPY; PHYSIOLOGY; RETINA NERVE CELL;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; KI-67 ANTIGEN; MICROSCOPY, PHASE-CONTRAST; NEUROGLIA; PLATELET-DERIVED GROWTH FACTOR; RETINAL NEURONS; SWINE; VITREOUS BODY;

EID: 84857987822     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-8683     Document Type: Article

References (34)

1. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48-58.
2. Guidry C. The role of Muller cells in fibrocontractive retinal disorders. Prog Retin Eye Res. 2005;24:75-86.
3. Sramek SJ, Wallow IH, Stevens TS, et al. Immunostaining of preretinal membranes for actin, fibronectin, and glial fibrillary acidic protein. Ophthalmology. 1989;96:835-841.
4. Weller M, Esser P, Heimann K, et al. Idiopathic proliferative vitreoretinopathy. Activation of microglial cells as the deciding factor [in German]. Ophthalmologe. 1992;89:387-390.
5. Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. Br J Ophthalmol. 1993;77: 731-733.
6. Hosoda Y, Okada M, Matsumura M, et al. Epiretinal membrane of proliferative diabetic retinopathy: an immunohistochemical study. Ophthalmic Research. 1993;25:289-294.
7. Hiscott P, Gray R, Grierson I, et al. Cytokeratin-containing cells in proliferative diabetic retinopathy membranes. Br J Ophthalmol. 1994;78:219-222.
8. Mizutani M, Gerhardinger C, Lorenzi M. Muller cell changes in human diabetic retinopathy. Diabetes. 1998;47:445-449.
9. Guidry C, King JL, Mason JO 3rd. Fibrocontractive Muller cell phenotypes in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009;50:1929-1939.
10. Guidry C. Tractional force generation by porcine Muller cells: development and differential stimulation by growth factors. Invest Ophthalmol Vis Sci. 1997;38:456-468.
11. Guidry C, Bradley KM, King JL. Tractional force generation by human Muller cells: growth factor responsiveness and integrin receptor involvement. Invest Ophthalmol Vis Sci. 2003;44:1355-1363.
12. Uchihori Y, Puro DG. Mitogenic and chemotactic effects of platelet-derived growth factor on human retinal glial cells. Invest Ophthalmol Vis Sci. 1991;32:2689-2695.
13. Ikeda T, Puro DG. Regulation of retinal glial cell proliferation by antiproliferative molecules. Exp Eye Res. 1995;60:435-443.
14. Moon SW, Chung EJ, Jung SA, et al. PDGF stimulation of Muller cell proliferation: contributions of c-JNK and the PI3K/Akt pathway. Biochem Biophys Res Commun. 2009;388:167-171.
15. Guidry C, Feist R, Morris R, et al. Changes in IGF activities in human diabetic vitreous. Diabetes. 2004;53:2428-2435.
16. King JL, Mason JO 3rd, Cartner SC, et al. The influence of alloxaninduced diabetes on Muller cell contraction-promoting activities in vitreous. Invest Ophthalmol Vis Sci. 2011;52:7485-7491.
17. Grant M, Russel B, Fitzgerald C, et al. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35:416-420.
18. Meyer-Schwickerath R, Pfeiffer A, Blum WF, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest. 1993;92:2620-2625.
19. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81: 228-233.
20. Burgos R, Mateo C, Canton A, et al. Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. Diabetes Care. 2000; 23:80-83.
21. Spranger J, Buhnen J, Jansen V, et al. Systemic levels contribute significantly to increased intraocular IGF- I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm Metab Res. 2000;32:196-200.
22. Spranger J, Mohlig M, Osterhoff M, et al. Retinal photocoagulation does not influence intraocular levels of IGF- I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy-evidence for combined treatment of PDR with somatostatin analogues and retinal photocoagulation? Horm Metab Res. 2001;33:312-316.
23. Hardwick C, Morris R, Witherspoon D, et al. Pathologic human vitreous promotes contraction by fibroblasts. Implications for proliferative vitreoretinopathy. Arch Ophthalmol. 1995;113:1545-1553.
24. King JL, Guidry C. Insulin-like growth factor binding proteins modulate Muller cell responses to insulin-like growth factors. Invest Ophthalmol Vis Sci. 2004;45:2848-2455.
25. Guidry C, King JL. Isolation and characterization of vitreous insulin-like growth factor binding proteins. Invest Ophthalmol Vis Sci. 2011;52:303-309.
26. Guidry C. Isolation and characterization of porcine Muller cells. Myofibroblastic dedifferentiation in culture. Invest Ophthalmol Vis Sci. 1996;37:740-752.
27. Guidry C, Grinnell F. Studies on the mechanism of hydrated collagen gel reorganization by human skin fibroblasts. J Cell Sci. 1985;79:67-81.
28. Ahlsen M, Carlsson-Skwirut C, Jonsson AP, et al. A 30-kDa fragment of insulin-like growth factor (IGF) binding protein-3 in human pregnancy serum with strongly reduced IGF-I binding. Cell Mol Life Sci. 2007;64:1870-1880.
29. Yan X, Payet LD, Baxter RC, et al. Activity of human pregnancy insulin-like growth factor binding protein-3: determination by reconstituting recombinant complexes. Endocrinology. 2009;150: 4968-4976.
30. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol. 1998;140: 19-24.
31. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278:E967-E976.
32. Ikeda T, Waldbillig RJ, Puro DG. Truncation of IGF-I yields two mitogens for retinal Muller glial cells. Brain Res. 1995;686:87-92.
33. Cassidy L, Barry P, Shaw C, et al. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol. 1998;82: 181-185.
34. Freyberger H, Brocker M, Yakut H, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2000;108:106-109.